Shimadzu: Cohort study on Alzheimer’s disease: Professor Sylvain Lehmann, Univ of Montpellier, France
Shimadzu:
Signed a joint research agreement with the University of Montpellier in France for the detection of Alzheimer’s lesions.
“Joint research agreement on the detection method of Alzheimer’s disease (amyloid accumulation)” with the University Hospital of Montpellier, France
Professor Sylvain Lehmann
Professor Christophe Hirtz et al.
In charge of analysis of accumulation of amyloid β*1 in blood using mass spectrometry. :
Professor Audrey Gabelle:
plan to evaluate the detection method through a cohort study*2.
Conventional Positron Emission Tomography (PET):
It is very different from imaging and cerebrospinal fluid (CSF) testing.
Our method:
The method for detecting amyloid β in blood has a small burden on the human body and is suitable for large-scale/survey research.
In 2014, Shimadzu Corporation and the National Center for Longevity Medical Research (NCGG) and others discovered this biomarker derived from blood.
2002/Nobel Prize in Chemistry: Koichi Tanaka/Executive Research Fellow
participating in this joint research.
The technology of “MALDI” (Matrix Assisted Laser Desorption/Ionization) has been useful in realizing the method for detecting Alzheimer’s disease (amyloid accumulation).
*2 Cohort study
Survey and prosecution methods in epidemiological research.
By observing a person who does not have a certain disease for a long time,
Examine whether or not a certain lifestyle is involved in the occurrence or prevention of disease.
2020 | News | Shimadzu
https://www.shimadzu.co.jp/news/press/k2zmkxgo1gvq7cn8.html
Cohort study: [National Cancer Center, Cancer Information Service for the general public]
https://ganjoho.jp/public/qa_links/dictionary/dic01/cohort_study.html